$GCTKJul 30, 2026, 9:29 PMAI processed8-K
Glucotrack/Lōkahi: nonclinical data supports testing LT-100 as single subcutaneous injection; clinical evaluation targeted Q4 2026
AI Summary
GCTK filed SEC Form 8-K. Subject to completion of ongoing development activities and regulatory review, Lōkahi currently anticipates initiating clinical testing of the single‐injection approach as early as Q4 2026 with an initial readout possibly in H1 2027.
Positives
- Nonclinical minipig study produced SC systemic exposure data Lōkahi says supports moving from multiple ID injections to a single SC injection.
- Company had a Type C meeting with FDA that helped define a path forward for the new administration approach.
- Company expects to begin clinical evaluation of the single‑injection approach as early as Q4 2026 with a potential initial readout in H1 2027.
Negatives
- No clinical data yet demonstrating safety or efficacy of the single SC injection—support is based on nonclinical data and regulatory discussion only.
- Planned clinical start and readout are conditional on completion of ongoing development activities and regulatory review; timings are forward‑looking and not guaranteed.